Clinical Scorecard: Antibiotic Management Strategies for Necrotizing Soft Tissue Infections: Insights from the Greater Paris SURFAST Consortium
At a Glance
Category
Detail
Condition
Necrotizing soft tissue infections (NSTIs), life-threatening infections causing extensive necrosis of skin and subcutaneous tissue
Key Mechanisms
Polymicrobial infections involving anaerobes, gram-positive and gram-negative bacteria; monomicrobial infections mainly by Streptococcus pyogenes; rapid tissue necrosis and systemic toxicity
Target Population
Patients with NSTIs, often with comorbidities such as diabetes, obesity, cardiovascular disease, immunosuppression, intravenous drug use; includes adults and pediatric populations
Care Setting
Acute hospital setting including intensive care units and surgical departments; multidisciplinary management involving infectious diseases, dermatology, intensive care, microbiology, pediatrics, and surgery
Key Highlights
NSTIs require urgent broad-spectrum intravenous antibiotic therapy combined with rapid surgical debridement and intensive care support.
Risk factors for ESBL-producing Enterobacterales and MRSA guide empirical antibiotic choices; carbapenems and anti-MRSA agents are reserved for patients with multiple risk factors or high severity.
Severe β-lactam allergy necessitates alternative antibiotic regimens; pediatric patients have higher prevalence of community-acquired MRSA, warranting anti-MRSA coverage.
Guideline-Based Recommendations
Diagnosis
Identify NSTIs based on clinical presentation of rapidly progressing skin and soft tissue necrosis.
Assess risk factors for ESBL-E and MRSA colonization or infection to guide empirical therapy.
Use SOFA score (>2 in adults) or Phoenix sepsis score (≥2 in children) to evaluate sepsis severity.
Management
Initiate broad-spectrum intravenous antibiotics promptly, targeting polymicrobial flora including anaerobes, streptococci, and Enterobacterales.
Perform rapid and extensive surgical debridement of all infected tissue.
Adjust empirical antibiotic therapy based on risk factors for ESBL-E and MRSA, local epidemiology, and patient severity.
Avoid empiric carbapenem use based on a single ESBL-E risk factor in low endemicity regions.
Include anti-MRSA coverage empirically in pediatric patients and in settings with high MRSA prevalence.
Monitoring & Follow-up
Monitor clinical response and organ function using SOFA or Phoenix scores.
Reassess antibiotic regimen based on microbiological results and patient progress.
Watch for signs of antibiotic allergy, especially in patients with history of severe β-lactam hypersensitivity.
Risks
High mortality (10–30%) and morbidity including amputations and reduced quality of life.
Risk of inappropriate antibiotic use leading to resistance, especially with unnecessary carbapenem use.
Potential severe allergic reactions in patients with β-lactam hypersensitivity.
Patient & Prescribing Data
Patients with necrotizing soft tissue infections in the greater Paris area, including adults and children with varying comorbidities and risk factors
Empirical antibiotic regimens are tailored based on individual risk factors for resistant organisms and severity; multidisciplinary consensus standardizes antibiotic management to improve outcomes.
Clinical Best Practices
Combine early broad-spectrum intravenous antibiotic therapy with prompt surgical debridement.
Use a multidisciplinary approach involving infectious diseases, surgery, intensive care, and microbiology experts.
Assess and incorporate patient-specific risk factors for resistant pathogens to guide empirical therapy.
Avoid unnecessary broad-spectrum antibiotics in low-risk patients to limit resistance development.
Include anti-MRSA coverage in pediatric patients and in high MRSA prevalence settings.
Carefully evaluate β-lactam allergy history to select safe alternative antibiotics.
by Caroline Charlier, Bérénice Souhail, Stéphane Dauger, Paul-Louis Woerther, Alexandre Bleibtreu, Marion Caseris, Olivier Chosidow, Chloé Bertolus, Camille Hua, Gentiane Monsel, Asmaa Tazi, Tomas Urbina, Benjamin Vérillaud, Philippe Montravers, Raphaël Lepeule, Nicolas de Prost
